QLT

Quility Bolsters Innovative Tech Offerings to Navigator Platform, Streamlining Agent Workflow and Improving Client Experience

Retrieved on: 
Tuesday, December 12, 2023

Navigator is a proprietary end-to-end digital life insurance distribution marketplace that creates a frictionless purchasing process with exclusive access to Quility's digital insurance products.

Key Points: 
  • Navigator is a proprietary end-to-end digital life insurance distribution marketplace that creates a frictionless purchasing process with exclusive access to Quility's digital insurance products.
  • "With these new product and platform enhancements, Quility Navigator's offerings are now more robust than ever before."
  • "With these new product and platform enhancements, Quility Navigator's offerings are now more robust than ever before," said Steve Fletcher, Quility President.
  • "By evolving our agent-forward tech offerings, Quility continues its commitment to bringing top-tier tools to the market."

Opthea strengthens its Board of Directors

Retrieved on: 
Friday, April 22, 2022

We welcome Quinton and Susan to our Board of Directors.

Key Points: 
  • We welcome Quinton and Susan to our Board of Directors.
  • Their addition to the board contributes greatly to the strength of the company.
  • I am excited to join the Board at this pivotal moment in Optheas history.
  • Dr. Orr currently serves as the Chief Medical Officer at Claris Biotherapeutics and is a member of the Retina Global Board of Directors.

Orum Therapeutics Appoints David Main to Board of Directors

Retrieved on: 
Wednesday, March 23, 2022

Orum Therapeutics , a biotechnology company pioneering the development of tumor-directed targeted protein degraders to treat cancer, today announced the appointment of David Main to the Companys Board of Directors.

Key Points: 
  • Orum Therapeutics , a biotechnology company pioneering the development of tumor-directed targeted protein degraders to treat cancer, today announced the appointment of David Main to the Companys Board of Directors.
  • David has extensive experience financing and leading biotech companies from early-stage research through commercial readiness, said Sung Joo Lee, Ph.D., Founder and CEO of Orum Therapeutics.
  • I welcome Davids insight as Orum advances into clinical trials the Companys first-in-class therapeutic candidates based on our Antibody neoDegrader Conjugate platform.
  • Orum Therapeutics is pioneering the development of tumor-directed targeted protein degraders by leveraging its TPD2 approach to provide dual precision, antibody-enabled targeted protein degraders for cell-specific delivery.

Zymeworks Names Biotechnology Industry Leader Kenneth Galbraith as Chair and CEO to Succeed Dr. Ali Tehrani

Retrieved on: 
Wednesday, January 5, 2022

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the appointment of Mr. Kenneth Galbraith as Chair and Chief Executive Officer (CEO) of Zymeworks, effective on or before February 1, 2022.

Key Points: 
  • Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the appointment of Mr. Kenneth Galbraith as Chair and Chief Executive Officer (CEO) of Zymeworks, effective on or before February 1, 2022.
  • Mr. Galbraith will succeed Zymeworks co-founder Ali Tehrani, Ph.D., who has served as President and CEO since 2003.
  • Dr. Tehrani will remain as an advisor to the Company to assist with the transition.
  • Zymeworks suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates.

Coherus BioSciences Mourns the Passing of Board Member Alan C. Mendelson

Retrieved on: 
Monday, October 11, 2021

REDWOOD CITY, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) -- It is with profound sadness that Coherus BioSciences, Inc.(Nasdaq: CHRS) announces the unexpected passing of board member Alan C. Mendelson.

Key Points: 
  • REDWOOD CITY, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) -- It is with profound sadness that Coherus BioSciences, Inc.(Nasdaq: CHRS) announces the unexpected passing of board member Alan C. Mendelson.
  • I am honored to have had him as a decades-long personal friend, inspiring mentor, and the most trusted of advisors.
  • On behalf of the entire Coherus team and Board, I offer our deep and heartfelt condolences to the Mendelson family.
  • In addition to his service on the Coherus board, Mr. Mendelson was General Counsel and Secretary at Blade Therapeutics and a Director of Neuvogen, Inc.